Among these, nearly half (44%) exhibited a markedly lower mutation rate in IP5, including TP53, ERBB2/4, MAP3K4, BRCA1, and PIK3CA. Further cases are needed to verify whether the heterogeneous immunogenicity of IBC is attributable to driver gene mutation signatures, as suggested in prior studies22. Here, MAP3K4 is linked to inflammatory breast carcinoma.